News

Introduction of OBI PHARMA, INC.’s

OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer

TAIPEI, TAIWAN, July 22/ — OBI Pharma, Inc., a Taiwan …

OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award

The Republic of China Venture Capital Association hosted its “Venture …

OBI Pharma Announces NT$ 1.5 Billion Capital Infusion

OBI Pharma, Inc. (GreTai Securities Market: 4174), announced a new …

OBI Pharma Wins the “Greatest Potential Award” at the 2013 Outstanding Biotech Awards

18 July 2013 – ROC President Ma Ying-jeou attended 2013 …

OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.

Taipei, Taiwan – 7 February 2013 – OBI Pharma, Inc. …

OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.

Taipei, Taiwan – 31 January 2013 – A recent paper …

OBI’s company English name official renamed OBI Pharma, Inc.

Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial

Breast Cancer New Drug:OBI-822/821 received Taiwan FDA Approval for entering …

DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD

DIFICID® (Fidaxomicin) Approved by Taiwan Department of Health for the …